sarepta nasdaq - Search News

News

Sarepta, Elevidys and European Medicines Agency

Sarepta shares drop after EU regulators reject Elevidys gene therapy

Shares of Sarepta Therapeutics Inc. (NASDAQ:SRPT) plunged 13% on Friday after a major regulatory blow in Europe. The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) issued a negative opinion on Elevidys,

· 20h · on MSN

Sarepta drops as report suggests FDA needs new trials for Elevidys

· 4h

Sarepta stock falls after Elevidys fails to get backing by EU regulators

Sarepta Therapeutics Acknowledges CHMP Negative Opinion for ELEVIDYS in the European Union

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, acknowledges that the ...

1don MSN

Sarepta Therapeutics (SRPT): “They Should Be Prosecuted,” Says Jim Cramer

We recently published 12 Stocks Jim Cramer Discussed As Analyzed Morgan Stanley’s Comments. Sarepta Therapeutics, Inc.

2don MSN

Arrowhead expects Sarepta to honor financial obligations

Arrowhead Pharmaceuticals (ARWR) stock gains as company reassures investors about financial obligations required from Sarepta ...

23h

Sarepta Therapeutics stock tumbles on concern about FDA study requirements

According to Endpoints News, FDA officials stated that the Center for Biologics Evaluation and Research (CBER) review staff are "unanimous" that Elevidys should never return to market. The report ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results